Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBT (2018 - 2025)

Historic EBT for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$15.2 million.

  • 10x Genomics' EBT rose 6859.65% to -$15.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$39.9 million, marking a year-over-year increase of 7754.25%. This contributed to the annual value of -$39.9 million for FY2025, which is 7754.25% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' EBT is -$15.2 million, which was up 6859.65% from -$28.2 million recorded in Q3 2025.
  • 10x Genomics' 5-year EBT high stood at $37.0 million for Q2 2025, and its period low was -$91.7 million during Q3 2023.
  • In the last 5 years, 10x Genomics' EBT had a median value of -$35.8 million in 2024 and averaged -$34.1 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 54100.22% in 2022, then skyrocketed by 19977.89% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' EBT stood at -$16.0 million in 2021, then fell by 2.61% to -$16.4 million in 2022, then plummeted by 183.94% to -$46.6 million in 2023, then dropped by 3.82% to -$48.4 million in 2024, then surged by 68.6% to -$15.2 million in 2025.
  • Its last three reported values are -$15.2 million in Q4 2025, -$28.2 million for Q3 2025, and $37.0 million during Q2 2025.